Skip to main content
SpringerLink
Log in

The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting

  • Short Communication
  • Published:
VirusDisease Aims and scope Submit manuscript

Abstract

The aim of this study was to compare efficacy and safety of different combination regimens in re-treatment of HCV in the setting of inaccessibility of resistance testing. This real-life prospective study included 86 chronic HCV infected patients who experienced failure of treatment treated at Faculty of Medicine Ain shams Research Institute (MASRI) since 2018. 64% of the patients were males, with median age 50.2 years. They were re-treated using 1 of 3 proposed regimens of DAA combinations. One group received PAR/OMB/SOF/RBV for 12 weeks, another group received SOF/DAC/SIM/RBV for 12 weeks and a third received SOF/DAC/RBV for 24 weeks. Response to different regimens was assessed by comparing sustained virologic response (SVR) of each. Monitoring the occurrence of adverse events was performed. SVR was achieved in all but 3 patients (96.5% SVR), one in the SOF/DAC/SIM/RBV group and two in the SOF/DAC/RBV group. The group receiving RBV had more anaemia and hyperbilirubinemia. The first treatment regimen used was a significant predictor to SVR achievement. This study presents alternative treatment regimens for re-treatment of HCV patients in areas with limited resources in the case of non-availability of other regimens as velpatasvir, voxilaprevir, grazoprevir, elbasvir.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Echeverríaa N, Betancoura G, Gámbaroa F, et al. Naturally occurring NS3 resistance-associated variants in hepatitis Cvirus genotype 1: their relevance for developing countries. Virus Res. 2016;223:140–6.

    Article  Google Scholar 

  2. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002. https://doi.org/10.1053/jhep.36227.

    Article  PubMed  Google Scholar 

  3. Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the AASLD and the American society of transplantation. Am Assoc Study Liver Dis. 2013. https://doi.org/10.1007/s13398-014-0173-7.2.

    Article  Google Scholar 

  4. World Health Organization. Hepatitis C, fact sheet n (164) [WWW document]. Hepat. C. 2015. https://doi.org/10.1016/S0140-6736(14)62401-6

  5. Reinoso H. Uncertainty and the treatment experience of individuals with chronic hepatitis C. J Nurse Pract JNP. 2016;12:445–51.

    Article  Google Scholar 

  6. US Centers for Disease Control and Prevention. Recommendations for identification of chronic hepatitis C virus infection among persons born during 1945–65; 2012.

  7. Mohlman MK, Ezzat S, et al. Viral transmission risk factors in an Egyptian population with high hepatitis C prevalence. BMC Public Health. 2015;15:1030.

    Article  Google Scholar 

  8. Hanno A, Elwazzan D, Ibrahim M, et al. A real-life study on treatment of Egyptian patients with HCV genotype IV with Simeprevir and Sofosbuvir. Health. 2016;8:780–6.

    Article  CAS  Google Scholar 

  9. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45–57.

    Article  Google Scholar 

  10. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486–504.

    Article  Google Scholar 

  11. Niederau C, Huppe D, Zehnter E, et al. Chronic hepatitis C: treat or wait? Medical decision making in clinical practice. World J Gastroenterol. 2012;18:1339–47.

    Article  CAS  Google Scholar 

  12. Lange CM, Jacobson IM, Rice CM, et al. Emerging therapies for the treatment of hepatitis C. EMBO Mol Med. 2014;6:4.

    Article  CAS  Google Scholar 

  13. Rueger S, Bochud PY, Dufour JF, et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut. 2015;64:1605–15.

    Article  CAS  Google Scholar 

  14. Wyles DL. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis. 2013;207:S33–9. https://doi.org/10.1093/infdis/jis761.

    Article  CAS  PubMed  Google Scholar 

  15. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol. 2011;55:192–206.

    Article  CAS  Google Scholar 

  16. Applegate TL, Gaudieri S, Plauzolles A, et al. Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C. Antivir Ther. 2015;20:199–208. https://doi.org/10.3851/IMP2821.

    Article  CAS  PubMed  Google Scholar 

  17. EASL Recommendations on Treatment of Hepatitis C. J Hepatol 2018, https://doi.org/10.1016/j.jhep.2018.03.026.

  18. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest. Hepatology. 2007;46(1):32–6.

    Article  CAS  Google Scholar 

  19. Garcia-Tsao G. The child-turcotte classification: from gestalt to sophisticated statistics and back. Dig Dis Sci. 2016;61(11):3102–4. https://doi.org/10.1007/s10620-016-4319-7.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Buti M, Riveiro-Barciela M, Esteban R. Management of direct-acting antiviral agent failures. J Hepatol. 2015;63(6):1511–22. https://doi.org/10.1016/j.jhep.2015.08.010.

    Article  PubMed  Google Scholar 

  21. Dvory-Sobol H, Wyles D, Ouyang W, et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir [abstract O059]. J Hepatol. 2015;62:S221.

    Article  Google Scholar 

  22. Krishnan P, Tripathi R, Schnell G, et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens [abstract O057]. J Hepatol. 2015;62:S220.

    Article  Google Scholar 

  23. Abdel-Moneim A, Aboud A, Abdel-Gabbar M, et al. A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure. J Hepatol. 2018;68:1313–35.

    Article  Google Scholar 

  24. Abdel-Moneim A, Aboud A, Abdel-Gabbar M, et al. Retreatment efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + ribavirin for hepatitis C virus genotype 4 patients. Dig Dis Sci. 2018;63:1341–7.

    Article  CAS  Google Scholar 

  25. Lawitz E, Poordad F, Gutierrez JA, et al. Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease. J Viral Hepat. 2017;24:287–94.

    Article  CAS  Google Scholar 

  26. Ismail WA, Wadea FM. The outcome of combined treatment with ombitasvir-paritaprevir-ritonavir, sofosbuvir with or without ribavirin as salvage therapy for Egyptian HCV experienced patients: a single center study. Drug Discov Therapeutic. 2018;12(6):368–73.

    Article  CAS  Google Scholar 

  27. Darweesh SK, Elsaeed K, Omar H, et al. High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: a real-life multicenter study. Expert Rev Gastroenterol Hepatol. 2019;13(9):907–14.

    Article  CAS  Google Scholar 

  28. Anand AC, Agarwal SK, Garg HK, et al. Sofosbuvir and ribavirin for 24 weeks is an effective treatment option for recurrent hepatitis C infection after living donor liver transplantation. J Clin Exp Hepatol. 2017;7(3):165–71.

    Article  Google Scholar 

  29. Zanaga LP, Santos AG, Ataíde EC, et al. Recurrent hepatitis C treatment with direct acting antivirals—a real life study at a Brazilian liver transplant center. Braz J Med Biol Res. 2019. https://doi.org/10.1590/1414-431X20198519.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Aqel B, Leise M, Hugo EV, et al. Multicenter experience usingLedipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 relapsers after simeprevir and sofosbuvir treatment. Ann Hepatol. 2018;17(5):815–21.

    Article  CAS  Google Scholar 

  31. Wyles D, Weiland O, Yao B, et al. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol. 2019;70(5):1019–23.

    Article  Google Scholar 

  32. Kumada H, Watanabe T, Suzuki F, et al. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol. 2018;53:566–75.

    Article  CAS  Google Scholar 

  33. Ahmed OA, Kaisar HH, Hawash N, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in treatment of a cohort of Egyptian patients with hepatitis C virus infection. Infect Disord Drug Targets. 2017;17(2):95–100.

    Article  CAS  Google Scholar 

  34. Abd-Elsalam S, Sharaf-Eldin M, Soliman S, et al. Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. Arch Virol. 2018;163(1):51–66.

    Article  CAS  Google Scholar 

  35. Ahmed OA, Kaisar HH, Badawi R, et al. Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. Infect Drug Resist. 2018;1(11):295–8.

    Article  Google Scholar 

  36. Ahmed OA, Elsebaey MA, Fouad MHA, et al. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. Infect Drug Resist. 2018;28(11):441–5.

    Article  Google Scholar 

  37. Ahmed OA, Safwat E, Khalifa MO, et al. Sofosbuvir plus daclatasvir in treatment of chronic hepatitis C genotype 4 infection in a cohort of Egyptian patients: an experiment the size of Egyptian Village. Int J Hepatol. 2018;2018:9616234.

    Article  Google Scholar 

  38. Abdelmoemen G, Khodeir SA, Abou-Saif S, et al. Prevalence of occult hepatitis C virus among hemodialysis patients in Tanta university hospitals: a single-center study. Environ Sci Pollut Res Int. 2018;25(6):5459–64.

    Article  CAS  Google Scholar 

  39. Said EM, Abdulaziz BA, El Kassas M, et al. High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir+ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience. Adv Virol. 2020;165:1633–9.

    CAS  Google Scholar 

  40. Mohamed AA, El-Toukhy NER, Said EM, et al. Hepatitis C virus: Efficacy of new DAAs Regimens. Infect Disord Drug Targets. 2019 Jan 20. doi: https://doi.org/10.2174/1871526519666190121114003. [Epub ahead of print]

  41. Tanaka Y, Agha S, Saudy N, et al. Exponential spread of hepatitis C virus genotype 4a in Egypt. J Mol Evol. 2004;58:191–5.

    Article  CAS  Google Scholar 

  42. Stuart CR, Ray RA, Carella A, et al. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis. 2000;182:698–707.

    Article  Google Scholar 

  43. El Raziky M, Fathalah WF, El-akel WA, et al. The effect of peginterferon alpha-2a vs. Peginterferon Alpha-2b in treatment of Naive chronic HCV genotype-4 patients: a single centre Egyptian study. Hepat Mon. 2013;13(5):e10069.

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the national committee for control of viral hepatitis (NCCVH), for the support for the study through the national programme.

Funding

Self-funded.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    Gina Gamal Naguib, Tari George Michael, Yehia Elshazly, Ossama Ashraf Ahmed & Hosam Samir Elbaz

  2. Department of Community, Environmental, and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    Maha Magdy Wahdan & Aya Mostafa

  3. Department of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    Hany Dabbous, Heba Ismail Saad Aly & Mohamed Kamal Shaker

  4. Department of Tropical Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt

    Magdy El-Serafy & Wahid Doss

  5. Department of Tropical Medicine and Infectious Diseases, Tanta University, Tanta, 35127, Egypt

    Sherief Abd-Elsalam

  6. Department of Pediatrics and Clinical Research Center, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    Manal Hamdy El-Sayed

Authors
  1. Gina Gamal Naguib
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tari George Michael
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yehia Elshazly
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maha Magdy Wahdan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aya Mostafa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ossama Ashraf Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hany Dabbous
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Heba Ismail Saad Aly
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mohamed Kamal Shaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hosam Samir Elbaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Magdy El-Serafy
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Wahid Doss
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Sherief Abd-Elsalam
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Manal Hamdy El-Sayed
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All the authors have participated in the research and have reviewed and agree with the content of the article after approval of ethical committee and under supervision of the national committee for control of viral hepatitis (NCCVH).

Corresponding author

Correspondence to Sherief Abd-Elsalam.

Ethics declarations

Conflict of interest

The authors report no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Naguib, G.G., Michael, T.G., Elshazly, Y. et al. The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting. VirusDis. 32, 582–588 (2021). https://doi.org/10.1007/s13337-021-00712-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13337-021-00712-4

Keywords

Search

Navigation